Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Delayed Emergence From Anesthesia
Interventions: Methylphenidate HCl, Placebo; Drug
Lead sponsor: Nicoleta Stoicea; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Interventions: Microwave ablation; Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Duarte, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Multiple Myeloma
Interventions: Pomalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 8
States / cities: Burbank, California • Encinitas, California • Fresno, California + 5 more

Conditions: Locally Advanced Breast Cancer (LABC)
Interventions: INGN 201; Genetic
Lead sponsor: Introgen Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: COVID-19 Prevention Network; Network
Eligibility: 2 Months and older
Enrollment: 26,211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 14
States / cities: Aurora, Colorado • Miami, Florida • Atlanta, Georgia + 9 more

Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
Interventions: Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154; Drug
Lead sponsor: Shattuck Labs, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Little Rock, Arkansas • Duarte, California • Chicago, Illinois + 2 more

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: oblimersen sodium, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years to 59 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
Interventions: Blinatumomab, Oncaspar, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Mercaptopurine, Methotrexate, Vincristine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 51 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rectal Cancer, Non-Small Cell Lung Cancer
Interventions: FEED-FF, Standard of Care (SUC); Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma, Ovarian Sarcoma, Gynandroblastoma, Thyroid Carcinoma, Embryonal Rhabdomyosarcoma of Vagina (Diagnosis), Embryonal Rhabdomyosarcoma of Uterus (Diagnosis), Embryonal Rhabdomyosarcoma of Cervix, Intracranial Sarcoma
Interventions: Not listed
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 0 Minutes to 100 Years
Enrollment: 3,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2036
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma
Interventions: doxorubicin, filgrastim, ifosfamide, biological response modifier therapy, brachytherapy, chemotherapy, colony-stimulating factor therapy, conventional surgery, cytokine therapy, intraoperative radiotherapy, radiation therapy, surgery; Drug · Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 216
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more

Conditions: Lymphoma, Nonneoplastic Condition
Interventions: bleomycin sulfate, filgrastim, ABVD regimen, BEACOPP regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 60 Years
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 423
States / cities: Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more

Conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: trastuzumab, Pertuzumab, docetaxel, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, Bevacizumab; Biological · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Carfilzomib, Rituximab, Cyclophosphamide, Doxorubicin hydrochloride, Vincristine sulfate, Prednisone, Pegfilgrastim, Acyclovir; Drug · Biological
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: Buffalo, New York • Cleveland, Ohio

Conditions: Stroke
Interventions: IMT Robotic Arm therapy; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Asthma
Interventions: PACE, PACE Plus; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: Up to 99 Years
Enrollment: 1,176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Surgery, Anaesthesia, Ventilator-Induced Lung Injury, Lung Injury, Pneumonia, Pneumothorax, Respiratory Distress Syndrome, Adult, Respiratory Insufficiency
Interventions: Not listed
Lead sponsor: European Society of Anaesthesiology; Other
Eligibility: 18 Years and older
Enrollment: 10,690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota

Conditions: Sexual Dysfunction, Physiological, Sexual Dysfunctions, Psychological
Interventions: Physical activity; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alcohol Use Disorder
Interventions: audit and feedback, educational meetings, and academic detailing to promote medication receipt, Acamprosate, naltrexone, or disulfiram; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: Not listed
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Interventions: Simvastatin 40mg; Drug
Lead sponsor: Marc Goodman; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes
Interventions: Exenatide, Glargine, Rapid-acting insulin analogs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Obstructive Sleep Apnea, Adherence, Patient
Interventions: adherence promotion techniques, Routine Care; Behavioral · Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Triple Negative Breast Cancer
Interventions: Placebo, Atezolizumab; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 1,550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 212
States / cities: Mobile, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 164 more

Conditions: Hypothermia Following Anesthesia, Hypothermia, Surgery
Interventions: EnsoETM, Surface Warming; Device
Lead sponsor: Advanced Cooling Therapy, Inc., d/b/a Attune Medical; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

General Anesthesia Emergence Induced by Methylphenidate

NEUWAVE Flexible Probe Study #2

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer

SARS-CoV-2/COVID-19 Prevalence Study

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

ALL Backbone in AYAs

High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

International PPB/DICER1 Registry

Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

The General Use of Robots in Stroke Recovery

Improving Asthma Outcomes Through Cultural Competence Training for Physicians

Local Assessment of Ventilatory Management During General Anesthesia for Surgery

Sexual Health on Antidepressants Through Physical Exercise

Promoting Medications for Alcohol Use Disorder on the General Medicine Service

Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Increasing Adherence to Oral Appliance Therapy for Obstructive Sleep Apnea

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Intraoperative Warming During Major Surgical Procedures Using the Esophageal Temperature Management System